



BioBeat 19

Accelerating Cell and Gene Therapy



GSK and Stevenage Bioscience Catalyst are delighted to host:

A summit to explore the UK advantage in Cell and Gene Therapy

For scientists, entrepreneurs and investors

13:00 – 18:00

Tuesday 19 November 2019

GSK R&D Stevenage Campus
Gunnels Wood Road
Stevenage SG1 2NY

#biobeat19 @BioBeatUK @GSK @SteBioCat

Agenda

Start	Finish	Session
13:00	– 13:20	Registration
13:20	– 13:30	Welcome Miranda Weston-Smith, Founder, BioBeat Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst Victoria Higgins, Senior Director, R&D, GSK
13:30	– 14:00	Keynote Emma Walmsley, CEO, GSK Creating the right innovation ecosystem in the UK for cutting-edge therapies
14:00	– 15:00	Panel 1: Leveraging science This panel lives the translational journey from scientific innovation to scale up of C> and asks where are the biggest opportunities? On the panel: Aisha Hasan, Clinical Development Head, Cell and Gene Therapy Oncology, GSK Giovanna Lombardi, Professor of Human Transplant Immunology, King's College London Emma Morris, Professor of Clinical Cell and Gene Therapy, UCL Institute of Immunity and Transplantation (Chair) Sophie Papa, Clinical Reader and Honorary Consultant Medical Oncologist, Guy's Cancer at Guy's and St Thomas' NHS Trust Jane Robertson, CMO, Achilles Therapeutics
15:00	– 15:30	Break
15:30	– 16:30	Panel 2: Optimising value This panel unwraps the drivers for value in C>, from commercial return to impact on health. On the panel: Natalie Hearmon, Consultant, Health Economics and Statistics Lead, Costello Medical Karen Hodgkin, previously COO, Cell Medica (Chair) Angela Osborne, MD, eXmoor Pharma Anna Outhwaite, Head of ATTC, Cell and Gene Therapy Catapult Tara Raveendran, Head of Life Sciences Research, Shore Capital Jane Whitrow, VP Business Operations, Freeline Therapeutics
16:30	– 16:35	Close and thanks
16:35	– 18:00	Refreshments & Networking

Thanks to our Partners

